Bullboard - Stock Discussion Forum Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints... see more

Add To Watchlist

NDAQ:APHA - Post Discussion

Aphria Inc. > I lied this is my last post. Take a look at the

View:

Post by CaneIsAbel on Apr 08, 2021 6:59pm

I lied this is my last post. Take a look at the

Numbers. We generated 160 million in net revenue last quarter. That's with massive recreational growth which has only grown far more with store openings by the day across Canada. We increased our presence in Poland. German lockdowns allow for in person doctor visits unlike last time which effected our German revenue with reduced prescriptions people couldn't get. And as I said we have SweetWater revenue to report which I believe will be 30 million plus. Take a look yourselves and ask the question where do analysts come up with numbers they do negatively.

Record gross revenue for adult-use cannabis of $72.1 million in the second quarter, an increase of 149% from prior year quarter, representing the seventh consecutive quarter of growth.
Net cannabis revenue of $67.9 millionin the second quarter, an increase of 99% from prior year quarter and an increase of 7% from prior quarter.
Net revenue of $160.5 million in the second quarter, an increase of 33% from prior year quarter and an increase of 10% from prior quarter.
Cash cost to produce dried cannabis per gram1 of $0.79 in the second quarter, a decrease of 9% from the prior quarter, which represents the fifth consecutive quarter of decreasing cost.
Recorded seventh consecutive quarter with positive adjusted EBITDA1 and positive adjusted EBITDA from cannabis business1.
Adjusted EBITDA from cannabis business1 of $12.9 million in the second quarter, an increase of 24% from the prior quarter.
Adjusted EBITDA1 of $12.6 million in the second quarter, an increase of 26% from the prior quarter.
Ended second quarter with a strong balance sheet and liquidity, including $320.0 million of proforma cash1 to fund planned Canadian and international growth.
Free cash flow1 improved $70 millionduring the second quarter predominantly as a result of increased cash provided by operating activities, as the Company better managed its working capital.
Completed first EU-GMP shipment of dried cannabis and cannabis oil to Germany.
Received import permit for first EU-GMP shipment of cannabis oil for sale and distribution in Malta.
Completed first shipment of medical cannabis to Canndoc for distribution in Israel.
Executed supply agreement with ODI Pharma AB, expanding Aphria's international presence into Poland.
Completed the accretive, strategic acquisition of SW Brewing Company, LLC, further diversifying the Aphria's product offering, broadening its consumer reach, and enhancing loyalty with consumers.
Expanded 510 vape offerings across Aphria's award-winning adult-use brand portfolio.